TuisGRAL • NASDAQ
add
Grail Inc
Vorige sluiting
$82,65
Dagwisseling
$83,71 - $92,79
Jaarwisseling
$12,76 - $103,00
Markkapitalisasie
3,22 mjd USD
Gemiddelde volume
1,14 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 35,54 m | 11,18% |
Bedryfskoste | 146,55 m | -37,88% |
Netto inkomste | -113,98 m | 92,81% |
Netto winsgrens | -320,69 | 93,53% |
Wins per aandeel | -3,18 | — |
EBITDA | -91,68 m | 49,34% |
Effektiewe belastingkoers | 25,43% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 602,75 m | -37,14% |
Totale bates | 2,70 mjd | -17,34% |
Totale aanspreeklikheid | 387,91 m | -32,48% |
Totale ekwiteit | 2,31 mjd | — |
Uitstaande aandele | 36,05 m | — |
Prys om te bespreek | 1,29 | — |
Opbrengs op bates | -11,79% | — |
Opbrengs op kapitaal | -13,48% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -113,98 m | 92,81% |
Kontant van bedrywe | -76,96 m | 55,20% |
Kontant van beleggings | 70,37 m | 5 177,13% |
Kontant van finansiering | — | — |
Netto kontantverandering | -6,47 m | -100,85% |
Beskikbare kontantvloei | -29,88 m | 75,95% |
Meer oor
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021 Galleroi launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024. Wikipedia
Gestig
2015
Webwerf
Werknemers
1 000
